Antinuclear Antibody Test Market report provides a detailed overview of the major drivers, challenges, opportunities, strategies impacting the market. The increasing prevalence of autoimmune diseases and increasing healthcare expenditure worldwide are the major factors driving the growth of this market.
The Global Antinuclear Antibody Test Market is expected to reach USD 1,476.1 Million, at a CAGR of 12.4%
Don’t miss out on business opportunities in Antinuclear Antibody Test Market
This report segments this Antinuclear Antibody Test Market based on products, diseases, techniques, end users, and regions. In the products market, the assay kits & reagents segment is expected to account for the largest share.
Role of Antinuclear Antibody Test Market in Hospitals;
The hospitals’ segment is expected to account for the largest share of the global Antinuclear Antibody Test Market. Growth in this segment can be attributed to the fact that most diagnostic tests are performed in hospitals or hospital-attached laboratories, primarily due to easy access to reports and smooth logistics.
Download PDF: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218189007
The prominent players in the Antinuclear Antibody Test Market include:
Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S. ), and Zeus Scientific, Inc. (U.S.).
Detailed analysis for one of the major key player:
Alere Inc. (U.S.) is the second-largest player in the global Antinuclear Antibody Test Market, with a share of 15.6% in 2014. Alere operates in more than 100 countries across the globe, including the U.S., Austria, Denmark, China, Brazil, Indonesia, South Africa, and Japan. The company focuses on new product launches to strengthen its portfolio.
Read More: https://www.marketsandmarkets.com/Market-Reports/antinuclear-antibody-test-market-218189007.html
